HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transdel, JMSR partner on anti-cellulite product

This article was originally published in The Rose Sheet

Executive Summary

Jan Marini Skin Research has secured one-year exclusive rights to market an anti-cellulite cosmeceutical product in the U.S. based on Transdel Pharmaceuticals' transdermal delivery technology. The San Jose, Calif., company also has obtained non-exclusive rights to promote and sell the product in dermatological markets outside the U.S. JMSR will pay Transdel royalties, according to June 17 release. Transdel's lead drug, which has completed a Phase 3 clinical trial, employs the firm's delivery technology to facilitate passage of a non-steroidal anti-inflammatory drug through the skin directly to underlying tissues with minimal systemic exposure. "We are very excited with the establishment of our relationship with JMSR and look forward to building on this relationship in order to potentially launch additional cosmeceutical products," says Transdel CFA and Acting CEO John Lomoro. Last year Transdel said it was exploring the efficacy of its delivery system in cosmeceuticals for treating varicose veins, hyperpigmentation and signs of aging, as well as cellulite, which it identified as a multibillion-dollar global opportunity (1"The Rose Sheet" April 6, 2009)
Advertisement

Related Content

Transdel Targeting Cellulite In ’09 While Finishing Trials For Anti-Pain Drug
Transdel Targeting Cellulite In ’09 While Finishing Trials For Anti-Pain Drug
Advertisement
UsernamePublicRestriction

Register

RS017026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel